SAN DIEGO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics, today announced positive ...
(MENAFN- GlobeNewsWire - Nasdaq) – Single subcutaneous dose of ADX-038 achieved near-complete alternative pathway suppression for 6 months, supporting potent and selective CFB silencing – – Phase 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback